Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

作者
Chiorean EG,Von Hoff D,Yi Wan,Sandra Margunato‐Debay,Marc Botteman,David Goldstein
出处
期刊:DOAJ: Directory of Open Access Journals - DOAJ 被引量:2
摘要

E Gabriela Chiorean,1 Daniel Von Hoff,2 Yin Wan,3 Sandra Margunato-Debay,4 Marc Botteman,3 David Goldstein5 1Medical Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, 2Oncology, Translational Genomics Research Institute and HonorHealth, Phoenix, AZ, 3Pharmerit International, Bethesda, MD, 4Celgene Corporation, Summit, NJ, USA; 5Department of Medical Oncology, Prince of Wales Hospital, Sydney, NSW, Australia Objectives: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient’s well-being during treatment with nab-paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial.Participants and methods: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and 1 month before disease progression) and for time to any KPS deterioration. Time to definitive KPS deterioration (≥10-point KPS decrease from baseline) was calculated using the Kaplan–Meier method. A larger decrease from baseline (≥20 points) was investigated as a sensitivity analysis. A Cox proportional hazards model analyzed the effect of baseline factors (including treatment) potentially associated with time to definitive deterioration.Results: The two treatment arms had generally comparable time to any KPS deterioration, similar KPS at 3 and 6 months after randomization and at 1 month before disease progression, and no significant difference in time to definitive deterioration. Baseline KPS, neutrophil-to-lymphocyte ratio, age, liver metastases, and region had a significant effect on time to definitive KPS deterioration, but treatment arm did not.Conclusion: The increased survival observed with nab-paclitaxel plus gemcitabine was not associated with adverse effects on performance status. Keywords: Karnofsky performance status, metastatic pancreatic cancer, chemotherapy, nab-paclitaxel, gemcitabine

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
肖肖发布了新的文献求助10
刚刚
Qiancheni发布了新的文献求助10
刚刚
1秒前
hqq完成签到,获得积分10
1秒前
魏同心发布了新的文献求助10
2秒前
2秒前
FIZZES完成签到,获得积分10
2秒前
科研通AI6.3的应助被泡芙墩墩采纳,获得10
3秒前
吉祥止止完成签到,获得积分10
3秒前
3秒前
3秒前
李健的应助被无奈醉柳采纳,获得10
5秒前
风中的眼神完成签到,获得积分10
5秒前
5秒前
dougsong完成签到,获得积分10
5秒前
叶林海发布了新的文献求助30
5秒前
务实白开水完成签到 ,获得积分0
5秒前
6秒前
7秒前
7秒前
7秒前
8秒前
orad完成签到,获得积分20
8秒前
ytg发布了新的文献求助10
9秒前
9秒前
terry完成签到,获得积分10
9秒前
Davin_ji完成签到 ,获得积分10
10秒前
10秒前
坚定的若枫完成签到,获得积分10
10秒前
苶凉完成签到,获得积分10
10秒前
小蘑菇的应助被科研通管家采纳,获得10
11秒前
Owen的应助被科研通管家采纳,获得10
11秒前
在水一方的应助被科研通管家采纳,获得10
12秒前
烟花的应助被科研通管家采纳,获得10
12秒前
12秒前
脑洞疼的应助被科研通管家采纳,获得30
12秒前
无花果的应助被GZH采纳,获得80
12秒前
大模型的应助被科研通管家采纳,获得10
12秒前
Orange的应助被科研通管家采纳,获得10
12秒前
隐形曼青的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193